CVI Investments, Inc. and Heights Capital Management, Inc. filed an amended Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 2,161,749 shares of Moleculin Biotech, Inc. common stock as of September 30, 2026.
Key Highlights
- Beneficial ownership: CVI Investments, Inc. and Heights Capital Management, Inc. each reported beneficial ownership of 2,161,749 shares of Moleculin Biotech common stock.
- Percent of class: The 2,161,749 shares represent 9.9% of Moleculin Biotech's outstanding common stock, according to the filing.
- Warrant-based position: The shares reported as beneficially owned consist entirely of shares issuable upon the exercise of warrants, the filing disclosed.
- Ownership cap: The warrants are not exercisable to the extent the total shares beneficially owned would exceed 9.99%, per the filing.
- Shares outstanding: The filing references 19,477,380 shares outstanding as of August 21, 2026, based on the company's Prospectus Supplement No. 2 filed on that date.
- Voting and dispositive power: Both reporting persons reported zero sole voting or dispositive power, with shared voting and dispositive power each at 2,161,749 shares.
CVI Investments and Heights Capital Disclose Joint Warrant-Based Position
According to the amended Schedule 13G filed November 16, 2026, CVI Investments, Inc., a Cayman Islands corporation, and Heights Capital Management, Inc., a Delaware corporation, jointly reported beneficial ownership of 2,161,749 shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) common stock, $0.001 par value per share. The event triggering the filing occurred on September 30, 2026. The filing is designated Amendment No. 1 to a prior Schedule 13G submission.
The filing states that the shares reported as beneficially owned "consists of Shares issuable upon the exercise of warrants to purchase Shares." The warrants contain a 9.99% beneficial ownership blocker, meaning they "are not exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its affiliates" would exceed that threshold. Heights Capital Management, Inc. serves as the investment manager to CVI Investments, Inc. and, the filing notes, "may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc." Neither reporting person holds sole voting or dispositive power over any of the shares.
The filing further notes that each of the reporting persons "disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein." The 9.9% figure is calculated against the 19,477,380 shares outstanding referenced in Moleculin Biotech's Prospectus Supplement No. 2, filed August 21, 2026. The statement was signed by Sarah Travis, identified as Assistant General Counsel and Assistant Secretary of Heights Capital Management, Inc., on November 12, 2026, with Heights Capital Management acting as authorized agent of CVI Investments pursuant to a previously filed Limited Power of Attorney.
What Was Disclosed
CVI Investments, Inc. and Heights Capital Management, Inc. filed an amended Schedule 13G disclosing a combined 9.9% beneficial ownership stake in Moleculin Biotech, Inc., consisting entirely of shares issuable upon warrant exercise, as of September 30, 2026.





Please wait processing your request...